Interius BioTherapeutics

About Interius BioTherapeutics

Interius BioTherapeutics is an early-stage biotechnology startup that is revolutionizing the field of cell and gene therapy. The company's primary focus is on developing advanced delivery technology for targeted gene delivery. This technology is based on the research of Dr. Saar Gill from the University of Pennsylvania.

Interius operates in the biotechnology market, specifically in the area of hematologic malignancies, a type of blood cancer. Their business model revolves around the development and commercialization of their proprietary technology platform. This platform enables the generation of chimeric antigen receptor (CAR) T cells directly within the body, a process known as in vivo generation.

Unlike traditional CAR T-cell treatments, which require cell manipulations outside the body (ex vivo) and potentially harmful pre-conditioning chemotherapy, Interius' approach eliminates these steps. This not only makes the treatment process less invasive and potentially less harmful, but it also opens up new possibilities for the use of genetic medicine in creating transformative therapies for patients.

Interius BioTherapeutics generates revenue through the development and potential future sales of its innovative gene therapy treatments. The company's primary clients are patients suffering from hematologic malignancies, although the technology has the potential to be applied to other diseases in the future.

The company prides itself on its collaborative and inclusive work culture, which it believes is key to its success. It is currently seeking passionate individuals to join its team and contribute to its mission of transforming the field of genetic medicine.